Cancer Conversations: Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022

Join us for this dynamic, case-based, CME-certified live webinar, in which an expert panel will discuss key areas of consensus and controversy involving existing and emerging BTK inhibitors therapies in CLL/SLL and MCL in a virtual talk-show format. Sign up today!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • BTK Inhibitor Therapy for Treatment-Naive Patients With CLL
  • BTK Inhibitor Therapy for Previously Treated Patients With CLL
  • Emerging BTK Inhibitor Therapies
  • BTK Inhibitor Therapy for Patients With MCL
  • Key Safety Considerations With BTK Inhibitor Therapy
  • Audience Question and Answer Session


Date / Time
Event Details


Program Director
Jeff Sharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.

Target Audience
This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate emerging BTK inhibitor data considering the potential impact of safety and efficacy results on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results
  • Select and sequence therapy for patients with resistance to or intolerance of first-line BTKi-based therapy to optimize clinical outcomes
  • Identify patients who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.